The Indian government is calling on the pharmaceutical sector to secure global supply chains by prioritizing quality standards and innovation, backed by major initiatives like Biopharma Shakti and updated procurement policies.

Government's Call to Pharma Industry for Global Leadership

Union Minister J.P. Nadda has urged India's pharmaceutical companies to take a leading role in stabilizing global supply chains through unwavering commitment to quality and cutting-edge innovation. Speaking at a recent industry event, he emphasized India's potential to evolve from being the world's pharmacy to a true innovation powerhouse. This push comes amid growing global uncertainties, including trade tensions and supply disruptions, where reliable partners are in high demand. Nadda highlighted how government policies are aligning to support this vision, encouraging firms to embed quality not just as compliance but as a core business principle. The minister's remarks reflect a broader strategy to position India as a trusted hub for everything from generics to advanced biologics, ensuring steady access to medicines worldwide.

This call to action is timely as India's pharma sector already supplies a significant portion of global generics and vaccines. By focusing on resilience, the government aims to reduce vulnerabilities exposed during recent pandemics and geopolitical shifts. Companies are being nudged to invest in domestic manufacturing, research, and technology to meet international standards and expand market reach.

Key Initiatives Boosting Quality and Supply Chain Strength

At the heart of this drive is the Biopharma Shakti programme, a massive ₹10,000 crore investment over five years announced in the Union Budget 2026. This flagship scheme targets strengthening production of biologics and biosimilars, areas critical for treating rising non-communicable diseases like diabetes and cancer. It includes upgrades to National Institutes of Pharmaceutical Education and Research (NIPERs), expansion of clinical trial sites to 1,000 nationwide, and bolstering the Central Drugs Standard Control Organisation (CDSCO) with specialized experts for faster, reliable approvals. These steps are designed to cut import dependence, create jobs, and build infrastructure that meets global benchmarks, making Indian products more competitive on the world stage.

Complementing this are ongoing efforts like the Production Linked Incentive (PLI) scheme for pharmaceuticals, the Strengthening of Pharmaceutical Industry (SPI) scheme, and Bulk Drug Parks. These focus on ramping up capacity for active pharmaceutical ingredients (APIs), upgrading small and medium enterprises to WHO-Good Manufacturing Practices, and creating shared facilities in pharma clusters. Additionally, the newly notified CGHS Drug Procurement Policy 2026 introduces technology-driven processes to ensure uninterrupted, high-quality medicine supply to millions of beneficiaries, setting a model for efficient procurement nationwide.

India is transitioning from the ‘pharmacy of the world’ to a global innovation hub, supported by a robust policy framework focused on healthcare security, manufacturing resilience, and scientific excellence. We need to transition from volume-driven growth to capability-led innovation, urging industry to anchor global supply chains with quality and trust.

Industry Response and Path Forward

Pharma leaders have welcomed these measures as a defining moment, calling them transformative for scaling up biopharma capabilities. Experts note that faster regulatory pathways and talent development for one lakh allied health professionals will address key bottlenecks, enabling quicker market entry for innovative therapies. The emphasis on emerging technologies like AI for better diagnostics, traceability, and quality control is seen as a game-changer, helping firms navigate complex global regulations and diversify exports beyond traditional markets like the US to regions in Europe, Africa, and Asia.

Challenges remain, such as tariff uncertainties and the need for skilled workforce expansion, but policy support like customs exemptions on life-saving drugs and incentives for advanced manufacturing are mitigating these. The government's holistic approach—linking manufacturing, R&D, clinical infrastructure, and regulation—signals a shift up the value chain, from affordable generics to high-value innovations. This positions India not just as a supplier but as a strategic partner in global healthcare security.

In summary, the government's urging of the pharma sector to anchor global supply chains via quality and innovation is backed by substantial investments and reforms like Biopharma Shakti and CGHS policy updates. These efforts promise enhanced resilience, job growth, and India's rise as a biopharma leader, benefiting patients worldwide with reliable, advanced medicines.

• Tags
• #Pharmaceuticals
• #Government
• #Healthcare